BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18941750)

  • 1. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
    Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of kahalalide F in advanced cancer patients.
    Miguel-Lillo B; Valenzuela B; Peris-Ribera JE; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):365-74. PubMed ID: 26093949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
    Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
    Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
    Geoerger B; Estlin EJ; Aerts I; Kearns P; Gibson B; Corradini N; Doz F; Lardelli P; Miguel BD; Soto A; Prados R; Vassal G
    Eur J Cancer; 2012 Feb; 48(3):289-96. PubMed ID: 22119199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and excretion of
    van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
    Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P
    Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.
    Ouellet D; Periclou AP; Johnson RD; Woodworth JR; Lalonde RL
    Cancer Chemother Pharmacol; 2000; 46(3):227-34. PubMed ID: 11021740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
    Mateos MV; Cibeira MT; Richardson PG; Prosper F; Oriol A; de la Rubia J; Lahuerta JJ; García-Sanz R; Extremera S; Szyldergemajn S; Corrado C; Singer H; Mitsiades CS; Anderson KC; Bladé J; San Miguel J
    Clin Cancer Res; 2010 Jun; 16(12):3260-9. PubMed ID: 20530693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.
    Agbo F; Bui KH; Zhou D
    J Clin Pharm Ther; 2017 Oct; 42(5):539-546. PubMed ID: 28474366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
    Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
    Salem AH; Koenig D; Carlson D
    Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.